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INTRODUCTION
The Acquired Immuno-Deficiency Syndrome 
(AIDS) outbreak started in 1981. HIV infected peo-
ple, predominantly previously healthy young men, 
started to develop diseases considered to be limited 
to the immunocompromised patients. Acquiring 
the HIV infection lead to an extremely reduced 
life expectancy in those years. The introduction of 
Highly Active Anti-Retroviral Therapy (HAART) 
in 1996 completely changed this scenario. Now-
adays, people living with HIV (PLWH) have an 
average life-length similar to the general population 
and new pathologies linked to adverse-effects of a 
life-long therapy, aging and HIV-related persistent 
inflammation emerged, leading to new issues to 
deal with and hopefully resolve1-22.
Infectious, inflammatory and neoplastic lung 
diseases have been a major co-morbidity in 
HIV-infected patients since the beginning of the 
HIV epidemic, because of the high prevalence of 
smokers within the HIV-positive population and 
the role played by viral and host factors. Lung 
cancer, the most common cancer in the world, 
heavily affects PLWH, representing today the 
leading cause of death in this population, having 
a three-fold higher incidence than general popu-
lation with the worst prognosis1-3,21,23-26.
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2diagnosis of lung cancer, pro-inflammatory cyto-
kines, such as IL-6, can be found to be elevated.
HIV could also have a direct oncogenic action 
in the development of lung cancer. Cribbs et al47 
demonstrated that a wide percentage of a small 
cohort of non-smoker PLWH with a suppressed se-
rological viral load, had detectable pro-viral DNA 
in alveolar macrophages. 
Further studies are needed to increase our knowl-
edge about lung cancer pathogenesis in PLWH, in 
order to prevent its development, if possible.
DIAGNOSIS
NoN-INvasIve screeNINg 
aNd dIagNostIc techNIques
Patients are mostly asymptomatic at early stages 
or they can have non-specific symptoms. Patients 
diagnosed at Stage I are commonly curable and 
have a 5-year survival rate of 50-80%28,30,48,49. 
Unfortunately, in PLWH the diagnosis is often 
delayed exactly because of the lack of specific 
symptoms. As a matter of fact, the most common-
ly reported symptoms in HIV patients with lung 
cancer are: cough, weight loss, dyspnea, night 
sweats, chest pain, and anorexia50-53. 
Screening of high-risk individuals is necessary 
to find the disease at an early stage and improve the 
patients’ survival. Moreover, it is fundamental in 
offering a better opportunity for treatment. Italian 
Guidelines for the management of HIV infection 
suggest that PLWH who smoke more than 30 pack 
of cigarettes per year should undergo a low-dose 
Computed Tomography (CT) scan40.
However, asymptomatic PLWH have a high 
prevalence of pulmonary nodules unrelated to 
lung cancer. Therefore, in 2004 the US Preventive 
Service Task Force concluded that a screening 
program of asymptomatic people for lung cancer 
was not cost-effective54-56 and in 2017 the Euro-
pean AIDS Clinical Society (EACS) still chose 
to not include lung cancer in their guidelines for 
the management of patients with HIV infection57.
In the suspect of lung cancer, the first examina-
tion performed is a chest x-ray. A wide spectrum of 
radiological signs can suggest the presence of a pri-
mary lung tumor, making a Computed Tomography 
(CT) necessary to confirm the diagnosis.
Recently, the emergence of combined PET/CT im-
aging has greatly aided the investigation of lung can-
cer; this technique has been shown to be an accurate 
tool for the work-up of solitary pulmonary nodules and 
improves the detection of metastatic disease58-61.
An accurate assessment of the disease extent is im-
portant to discern the best management: surgery, che-
motherapy, radiotherapy or any combination of them62-69.
Independent factors specifically associated with 
HIV infection, such as a direct oncogenic action, 
recurrent lung infections and immune depression, 
contribute to this increased risk; then, lung cancer 
is nowadays the most common non-AIDS defining 
cancer (NADC) in HIV patients23,25,27.
In this report, we review the diagnostic and 
therapeutic management of lung cancer in HIV 
infected patients.
RISK FACTORS AND PATHOGENESIS
The likelihood of developing lung cancer is related 
to the increase of the mean age in PLWH1,28-30. 
After the introduction of HAART, life expectancy 
of PLWH has considerably increased, leading to a 
directly proportional rise in the prevalence of lung 
cancer31-35. Male sex is related with the highest 
risk, probably because of the higher prevalence of 
HIV-infection and smoke in men than women36,37.
Smoking is the most important risk factor. 
HIV-infected smokers seem to develop lung can-
cer at a younger age than non-smokers. Bonnet et 
al38 claim that 90% of the PLWH died from lung 
cancer during a period going from 2000 to 2005. 
Smoking history is crucial for the development of 
lung cancer, seen that a 20 to 35 pack-year smoking 
history has been associated with the development 
of lung cancer in PLWH39. A number ≥ 30 of pack 
years is one of the parameters used for determin-
ing the need of lung cancer screening in PLWH, 
as suggested in the 2017 Italian’s HIV-guidelines40.
Persistent lung inflammation due to recurrent 
infections can only partially explain the increased 
risk of developing lung cancer in PLWH, and Shebl 
et al41 demonstrated that pneumonitis, but not tu-
berculosis or PCP, is associated with an increase 
in lung cancer incidence. However, this association 
was not confirmed when adjusted for smoking. 
As reported by Sigel et al42, Drummond et al43 
and Crothers et al44, Chronic Obstructive Pulmo-
nary Disorders (COPDs) are major risk factors 
for developing a lung cancer in PLWH who, in 
addition, have a higher risk of developing COPD 
because of an increased lung inflammation, in a 
vicious cycle that seems to have no escape.
HIV infection also brings with itself a series 
of risk factors related to immunosuppression, 
inflammation, viral oncogenesis, and HAART42.
A low CD4+ T-cell count is reported to be as-
sociated to an increased incidence of lung cancer 
incidence in more than one longitudinal study, 
which highlighted that PLWH who do not recover 
a CD4+ count of at least 500/mL during their life 
are at increased risk of developing it42,45. More-
over, Borges et al46 highlighted how, before the 
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Many authors investigated about noninvasive and 
molecular methods to detect and monitor tumors. 
Micro-RNAs, a group of endogenous and non-cod-
ing RNAs working as post-transcriptional regula-
tors of gene expression by affecting the stability 
and translation of mRNAs, are currently under 
investigation for being involved in development, 
invasion and metastasis of tumors, playing a role 
as both tumor suppressors and oncogenes. Wang 
et al70, starting from an observation of Zhao et al71, 
showed that the serum miR-411 levels increase in 
patients with NSCLCs and are significantly asso-
ciated with TNM stage, differentiation degree and 
survival. Therefore, it can be concluded that miR-
411 works as a tumor promoter in lung cancer, 
and particularly in NSCLC. This result may have 
clinical potentials and this marker could be used 
as a non-invasive diagnostic/prognostic biomarker.
Long noncoding RNAs, poorly conserved and 
not translated into proteins transcripts, are also 
currently being studied in search for any associ-
ation with the development of neoplasms.
Speaking of NSCLCs, several studies ob-
served that LINC00152 was upregulated in both 
NSCLC tissues and plasma samples of patients 
affected by lung cancer. Moreover, levels of plas-
ma/serum LINC0052 in patients affected by NS-
CLC are significantly higher than those expressed 
in patients affected by benign lung diseases or 
healthy controls72-75.
Two other lncRNAs (DKFZP434 L187 and 
LOC285548) are correlated with lung adenocarcino-
ma and may have prognostic value for the survival72. 
Aldehyde dehydrogenase 1 family, member 
A1 (ALDH1A1) is highly expressed in non-small-
cell lung cancer and studies demonstrated that 
ALDH1A1 correlated with carcinogenesis and 
progression of NSCLCs76-80. Further studies are 
required to establish the ability of these biomark-
ers to discriminate between inflammation during 
lung diseases and cancer. Moreover, studies in-
cluding PLWH are needed to determine if these 
soluble biomarkers are equally related to lung 
cancer in this population.
classIfIcatIoN of luNg caNcer
In 2015, the World Health Organization (WHO) 
published a new textbook of lung cancer clas-
sification with a number of important changes, 
compared to previous editions81. 
Unrepressed cell growth, tissue invasion and 
the development of metastasis due to anomalous 
expression of oncogenes are distinguishing signs 
of a cancer cell. In PLWH the risk to develop a 
neoplasm is increased because of the role played 
by HIV protein Tat in regulating cell prolif-
eration22,82,83. However, as previously discussed, 
studies failed in finding a link between HIV viral 
load and lung cancer84-86.
There are two major types of lung cancer 
classified as non-small cell lung cancer (NSCLC) 
and small cell lung cancer. The new WHO classi-
fication includes types and subtypes of epithelial 
tumors, such as: adenocarcinoma (subtypes acinar, 
papillary, micropapillary); squamous cell carcino-
ma (types: keratinizing squamous cell carcinoma, 
non-keratinizing squamous cell carcinoma, basa-
loid); neuroendocrine tumors (small cell carcino-
ma and large cell carcinoma). The non-epithelial 
tumors are included in specific tables87-89. The 
extension of a tumor is definite by the TNM clas-
sification90-93. The most frequently encountered 
cancers in HIV-patients are NSCLCH. The most 
common histologic type of lung cancer is ade-
nocarcinoma (67%), followed by squamous cell 
carcinoma, large cell carcinoma and bronco-alve-
olar carcinoma; small cell lung cancer comprises 
a small group with unidentified subtypes3,23,94-97.
THERAPIES
The first step to obtain a better outcome is a proper 
diagnosis with an accurate staging of the cancer 
and the application of the principles of person-
alized medicine. Surgery remains the treatment 
of choice and has an important role in definitive 
management of lung cancer98,99. Early stages (I-II) 
are usually treated with surgery and evaluation 
of the lymph nodes. Darling et al100 showed that, 
for patients treated with a resection of the tumor 
in an early stage, the disease-free rate at 5 years 
was 68%93. Lobectomy is the current technique for 
lung cancer resection; in the case of small tumors, 
a sub-lobar resection removing a small portion of 
pulmonary tissue may be used101. 
Advanced stages (III) of lung cancer need to be 
treated with combination therapies102. The use of 
chemotherapy or radiation before surgery (neoadju-
vant therapy) may help the surgeon to remove the 
mass reducing its diameter. Evidence suggests that 
chemotherapy after surgery may help to prevent a 
relapse (adjuvant therapy)103. Targeted treatments are 
a new option for the management of NSCLCs. Sev-
eral monoclonal antibodies are currently used, like 
Erlotinib and Afatinib, inhibitors of the epithelial 
growth factor receptor of the tyrosine-kinase fami-
ly104-106, or Crizotinib, an inhibitor of the anaplastic 
lymphoma kinase and the c-ros oncogene 1107.
Immunotherapy is generally well-tolerated 
and has recently emerged as a new treatment 
possibility with significantly improved outcomes 
in patients affected by lung cancers. 
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Two different immune checkpoint inhibitors 
that target Programmed Cell Death 1 (PD-1) and 
Programmed Death-Ligand 1 (PD-L1) have been 
discovered during the past years. These inhibitors 
seem to be effective even against metastatic NS-
CLCs and play an inhibitory function on T-cells 
activation in peripheric tissues108.
Several studies109,110 have been performed to 
define the interactions between HIV disease and 
immune checkpoint molecules. However, there 
is poor evidence that the immunotherapies can 
be used in patients with immune-compromised 
systems like HIV-positive people are. Marra et 
al111, published a paper describing the use of im-
munotherapy in PLWH affected by melanoma. 
Furthermore, the American Cancer Association 
(ACA) suggests that patients with HIV should no 
longer be excluded from new therapies for cancer. 
Furthermore, a study by ACA highlighted how the 
PD-1 inhibitor pembrolizumab does not show sig-
nificant risks for patients with HIV and cancer112.
CONCLUSIONS
Lung cancer has a high incidence and mortality, 
independently from HIV serological status. Be-
cause of that, it is a major worldwide public health 
problem. Early diagnosis is crucial. Detection of 
the cancer in an early stage means that a patient’s 
disease-free at 5 years survival is over 60%. Fur-
thermore, when a lung cancer is detected at an 
early stage, a curative treatment such as surgery 
is possible. Whenever it is possible, advanced 
tumors must be treated with combined treatments 
of surgery, chemo and radiotherapy. A pharma-
cological approach in advanced stage cancers is 
possible with the new experimental drugs, but 
guidelines for the use of monoclonal antibodies in 
HIV-patients with lung cancer are needed.
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